Guidance

Respiratory Syncytial Virus (RSV) vaccine: VGD template

Vaccine Group Direction (VGD) template to support the national vaccination programme for pregnant women to protect infants and selected older adults as outlined in the RSV system letter.

• From: UK Health Security Agency
• Published: 29 July 2026

Applies to England

Documents

Respiratory Syncytial Virus (RSV) vaccine: VGD template

Ref: GOV-21471

MS Word Document, 219 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This VGD template supports the administration of the RSV vaccine to:

• women from 28 weeks of pregnancy
• older adults aged 75 years and above
• residents in care homes for older adults
• older adults aged 65 to 74 years with chronic respiratory disease or immunosuppression due to disease or treatment, as outlined in Table 1 of the RSV Green Book chapter

in accordance with the national programme as outlined in the RSV letter and the RSV Green Book chapter.

The RSV vaccine VGD version 1.0 is valid from 1 September 2026 to 31 August 2029.

Practitioners must not use this template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This VGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 29 July 2026